JOURNAL BROWSE
Search
Advanced SearchSearch Tips
A Case Study on the FDA Approval of Medical Treatments against Nerve Agent Poisoning
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
A Case Study on the FDA Approval of Medical Treatments against Nerve Agent Poisoning
Lee, Keunwoo; An, Seoyeon; Hur, Byungil;
  PDF(new window)
 Abstract
The US Army used MARK-1 composed of atropine autoinjector and 2-PAM autoinjector as a medical countermeasure against nerve agent poisoning. Recently, it has been being replaced by the ATNAA(Antidote Treatment Nerve Agent AutoInjector) for improvement the convenience in use and rapid detoxification effect. ATNAA(FDA approval, NDA 21-175, 2002. 1. 17) is a multi-chambered autoinjector that sequentially delivers atropine and 2-PAM through a single needle to allow Warfighters to survive against lethal exposure to nerve agents. In this paper, our group investigated the case of FDA approval of ATNAA in a point of the various data required by FDA guideline, thereby making it easy to meet the KFDA guideline for the approval of the prototype our group has been developed. The purpose of this study is to provide a reference for efficient research activities to minimize time and cost. Additionally, the purpose of this study is to provide a reference for the planning for the development of similar drug.
 Keywords
Antidote;Nerve Agent;Autoinjector;
 Language
Korean
 Cited by
 References
1.
LTS Lohmann Therapie-System AG(German), Prophylactic Transdermal Device Against Nerve Agent, White Paper, April, 2002.

2.
Shih, T.-M., "Time Course Effects of Soman on Acetylcholine and Choline Levels in Six Discrete Areas of the Rat Brain," Psychopharmacology, Vol. 78, pp. 170-175, 1985.

3.
Lim, D. K., Lee, Porter, A. B., Hoskins, B. Ho, I. K., "Changes in ACh Levels in the Rat Brain During Subacute Administration of Diisopropyl Fluorophosphate," Toxicol. Appl. Pharmacol., Vol. 90, pp. 477-489, 1987b. crossref(new window)

4.
Kim, Y.-B., Phi, T.-S., Hur, G.-H., Cheon, K.-C., "Clinical Considerations the Use of Pyridostigmine," Ground Weapon Systems Res. Dev. 7th Symp., pp. D91-D101, 1999b.

5.
Dretchen, K. L., Bowles, A. M., Rains, A., "Protection by Phenytion and Calcium Channel Blocking Agents Againsts the Toxicity of Diisopropylfluorophosphate," Toxicol. Appl. Pharmacol., Vol. 83, pp. 584-589, 1986. crossref(new window)

6.
Rickett, D. J., Glenn, J. F., Beers, E. T., "Central Respiratory Effects Versus Neuromuscular Actions of Nerve Agents," Neurotoxicology, Vol. 7, pp. 225-236, 1986.

7.
Dunn, M. A. Sidell, F. R., "Progress in Medical Defence Against Nerve Agents," JAMA, Vol. 262, pp. 649-652, 1989. crossref(new window)

8.
Loomis, T. A., Salafsky, B., "Antidotal Action of Pyridinium Oximes in Anticholinesterase Poisoning ; Comparative Effects of Soman, Sarin, and Neosigmine on Neuromuscular Function," Toxicol. Appl. Pharmacol., Vol. 5, pp. 685-701, 1963. crossref(new window)

9.
Berman, H. A., Decker, M. M., "Kinetic, Equilibrium, and Spectroscopic Studies on Dealkylation ('aging') of Alkyl Organophosphonyl Acetylcholinesterase," J. Biol. Chem., Vol. 261, pp. 10646-10652, 1986.

10.
http://www.samyangchem.com

11.
http://www.meridianmeds.com

12.
O. Napoleon Monroe, N. Lawrenc Dalling, Clarence M. Mesa., "Dispersion Multichamber Auto-Injector," USP 5,092,843, 1992.

13.
http://www.fda.org